GlaxoSmithKline has announced the appointment of Maya Martinez-Davis as the new president of its US pharmaceuticals business.
She will join the company in September of this year and assume her new role on 1 January 2020.
Presently, Martinez-Davis serves as the regional president of the Latin America Region at EMD Serono, the biopharmaceutical business of Germany's Merck KGaA.
Before joining Merck, she spent 13 years at Pfizer in leadership roles in various business units around the world, including oncology and vaccines.
'Valuable US Experience'
Commenting on the appointment, GSK president of global pharmaceuticals, Luke Miels, said, "As we continue to grow and reshape our business globally, we are pleased to have found a leader in Maya who will bring a valuable US experience and deep therapy area expertise to expanding our specialty care capabilities and market presence."
Martinez-Davis will succeed Jack Bailey, who has stepped down from the role after a stint of more than 10 years in the company, and a career spanning nearly three decades in the life sciences industry.
'Significant Contribution'
“Jack is an exceptional leader who has made a very significant contribution to the success of GSK during his decade of leadership in the US," Miels added.
Bailey will serve as a strategic consultant to GSK on the US external environment through 2020, the company said.
© 2019 European Supermarket Magazine – your source for the latest retail news. Article by Dayeeta Das. Click subscribe to sign up to ESM: European Supermarket Magazine.
